NCT00367432View on ClinicalTrials.gov

A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures

PHASE3CompletedINTERVENTIONAL

Enrollment

398

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

EpilepsiesPartial

Interventions

DRUG

Levetiracetam

Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).

Trial Locations (53)

Unknown

Aichi-gun

Nagoya

Hirosaki

Matsudo

Kitakyushu

Koga

Kurume

Fukuyama

Asahikawa

Hakodate

Sapporo

Kobe

Kahoku-gun

Kanazawa

Zentsujichó

Kōshi

Tsu

Iwanuma

Sendai

Ōmura

Kashihara

Nagaoka

Beppu

Izumi

Neyagawa

Suita

Takatsuki

Iruma-gun

Shimotsuga-gun

Shimotsuke

Komatsushimachō

Chiyoda-Ku

Kodaira

Kokubunji

Shinjuku-ku

Taito-ku

Ube

Aomori

Chiba

Fukuoka

Fukushima

Gifu

Hiroshima

Kagoshima

Kumamoto

Kyoto

Miyazaki

Niigata

Okayama

Osaka

Shizuoka

Toyama

Yamagata

All Listed Sponsors

lead

UCB Japan Co. Ltd.

INDUSTRY

NCT00367432 - A Long Term Follow up Administration Study of L059 (Levetiracetam) in Epilepsy Patients With Partial Onset Seizures | Biotech Hunter | Biotech Hunter